Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | BRD2 | P25440 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5422437 | 0.93 | MITF (0.35) | LMNATSHRSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL20997112 | 0.81 | BRD4 (0.39) | LMNATSHRBRD4BRD2SMN1; SMN2 | |
| SCHEMBL353225 | 0.79 | LMNA (0.42) | LMNATSHRBRD4BRD2SMN1; SMN2 | |
| SCHEMBL28078795 | 0.79 | LMNA (0.42) | LMNATSHRBRD4BRD2SMN1; SMN2 | |
| SCHEMBL28310972 | 0.78 | LMNA (0.31) | LMNA | |
| SCHEMBL11037068 | 0.78 | LMNA (0.41) | LMNATSHRBRD4BRD2ALDH1A1 | |
| SCHEMBL28763465 | 0.78 | SLC6A2 (0.33) | — | |
| SCHEMBL24783971 | 0.76 | LMNA (0.39) | LMNATSHRBRD4BRD2SMN1; SMN2 | |
| SCHEMBL14693972 | 0.76 | LMNA (0.39) | LMNATSHRBRD4BRD2ALDH1A1 | |
| SCHEMBL22749300 | 0.76 | LMNA (0.39) | LMNATSHRBRD4BRD2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111349936-B | Super-amphiphilic neutral metal surface roughening treatment liquid and preparation method and application thereof | 株洲绿智新材料科技有限公司 | 2022-01-07 | — | — | CN | claimed |
| CN-111349936-A | Super-amphiphilic neutral metal surface roughening treatment liquid and preparation method and application thereof | 株洲绿智新材料科技有限公司 | 2020-06-30 | — | — | CN | claimed |
| CN-102574869-A | 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives | UCB PHARMA SA | 2012-07-11 | — | — | CN | claimed |
| CN-119317626-A | Pyrrolidone derivatives as inhibitors of NF- κb-induced kinase | 詹森药业有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-116964046-B | PLK4 inhibitors and uses thereof | 上海齐鲁制药研究中心有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-116964046-A | PLK4 inhibitors and uses thereof | 上海齐鲁制药研究中心有限公司 | 2023-10-27 | — | — | CN | disclosed |
| WO-2022184049-A1 | PLK4 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2022-09-09 | — | — | WO | disclosed |
| CN-110049985-B | Heterocyclic sulfones as ROR gamma modulators | 百时美施贵宝公司 | 2022-05-31 | — | — | CN | disclosed |
| US-11254651-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| CN-111349936-B | Super-amphiphilic neutral metal surface roughening treatment liquid and preparation method and application thereof | 株洲绿智新材料科技有限公司 | 2022-01-07 | — | — | CN | disclosed |
| CN-111349936-A | Super-amphiphilic neutral metal surface roughening treatment liquid and preparation method and application thereof | 株洲绿智新材料科技有限公司 | 2020-06-30 | — | — | CN | disclosed |
| US-20080114169-A1 | Isotopically enriched N-substituted piperazines and methods for the preparation thereof | APPLIED BIOSYSTEMS, LLC | 2008-05-15 | — | — | US | disclosed |
| US-20080114169-A1 | Isotopically enriched N-substituted piperazines and methods for the preparation thereof | APPLIED BIOSYSTEMS, LLC | 2008-05-15 | — | — | US | disclosed |
| US-7355045-B2 | Isotopically enriched N-substituted piperazine acetic acids and methods for the preparation thereof | APPLERA CORPORATION (US) | 2008-04-08 | — | — | US | disclosed |
| US-7355045-B2 | Isotopically enriched N-substituted piperazine acetic acids and methods for the preparation thereof | APPLERA CORPORATION (US) | 2008-04-08 | — | — | US | disclosed |
| CN-100364971-C | Pyrrolidin-2-ones as factor Xa inhibitors | GLAXO GROUP LTD (GB) | 2008-01-30 | — | — | CN | disclosed |
| CN-101094847-A | Aryloxy-substituted benzimidazole derivatives | BANYU PHARMA CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| US-7307169-B2 | Isotopically enriched N-substituted piperazines and methods for the preparation thereof | APPLERA CORPORATION (US) | 2007-12-11 | — | — | US | disclosed |
| US-7307169-B2 | Isotopically enriched N-substituted piperazines and methods for the preparation thereof | APPLERA CORPORATION (US) | 2007-12-11 | — | — | US | disclosed |
| CN-1620434-A | Pyrrolidine-2-ones as factor Xa inhibitors | GLAXO GROUP LTD (GB) | 2005-05-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114169-A1 | Isotopically enriched N-substituted piperazines and methods for the preparation thereof | ALKBH5, NPEPPS, PNMT | LMNA 2055/4885TSHR 4622/4885BRD4 275/4885 |
| US-11254651-B2 | Histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | LMNA 494/4885TSHR 3939/4885BRD4 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.